Global InformationBebtelovimab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Spike protein of SARS-CoV-2 |
| Clinical data | |
| Pronunciation | /ˌbɛbtɪˈloʊvɪmæb/ BEB-tih-LOHV-ih-mab[1] |
| Other names | LY-CoV1404, LY3853113 |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG |
|
Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.[2][3][4][5]
Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting.[2]
Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death.[2] Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.[6]
As of November 2022[update], bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.[7]
- ^ "Emergency Use Authorization (EUA) for the Treatment of COVID-19". Lilly. Archived from the original on 28 July 2022. Retrieved 28 July 2022.
- ^ a b c "FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant" (Press release). U.S. Food and Drug Administration (FDA). 11 February 2022. Archived from the original on 12 February 2022. Retrieved 12 February 2022.
This article incorporates text from this source, which is in the public domain.
- ^ "Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19" (Press release). Eli Lilly and Company. 11 February 2022. Archived from the original on 11 February 2022. Retrieved 12 February 2022 – via PR Newswire.
- ^ "AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19" (Press release). AbCellera. 11 February 2022. Archived from the original on 11 February 2022. Retrieved 12 February 2022.
- ^ Suran M (March 2022). "Federal Government Buys Thousands of Bebtelovimab Doses". JAMA. 327 (12): 1117. doi:10.1001/jama.2022.3520. PMID 35315904. S2CID 247599102.
- ^ "Bebtelovimab (Code C182122)". National Cancer Institute. Archived from the original on 13 February 2022. Retrieved 12 February 2022. This article incorporates text from this source, which is in the public domain.
- ^ "FDA Announces Bebtelovimab is Not Currently Authorized in the US". U.S. Food and Drug Administration. 30 November 2022. Retrieved 1 December 2022. This article incorporates text from this source, which is in the public domain.
